Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NasdaqGS: PGNX) to Lantheus Holdings, Inc. (NasdaqGS: LNTH). Under the terms of the proposed transaction, shareholders of Progenics will receive only 0.2502 shares of Lantheus for each share of Progenics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or fill out the form on this page.